|
||||||||||||||||||||||
|
|
Alternate Title Phase III Randomized Study of Letrozole in Preventing Breast Cancer in Postmenopausal Women With the BRCA1/BRCA2 Mutation
Trial Description Letrozole may prevent breast cancer in postmenopausal women with a BRCA1 or BRCA2 mutation. This randomized phase III trial is studying letrozole to see how well it works compared with a placebo in preventing breast cancer in postmenopausal women with a BRCA1 or BRCA2 mutation. Eligibility criteria include the following:
Final eligibility for a clinical trial is determined by the health professionals conducting the trial. Patients will be randomly assigned (have an equal chance of being placed) to one of two treatment groups. Patients in group one will receive letrozole by mouth once a day. Patients in group two will receive a placebo by mouth once a day. Treatment in both groups may continue for up to 5 years. Patients will undergo blood sample collection periodically for laboratory studies. After finishing treatment, patients will be evaluated for 5 years. Important: For more details about this trial, refer to the Health Professional version of the trial summary. If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site. Trial Lead Organizations Federation Nationale des Centres de Lutte Contre le Cancer
|
NCI Home |
Images Version |
Contact Us |
Policies |
Accessibility |
Viewing Files |
FOIA |
Site Help |
Site Map
|
A Service of the National Cancer Institute |